We use cookies necessary to giving you a better online experience. By using our website you consent to all cookies in accordance with our Privacy Policy.
Yes, I accept
Menu
Search Opener
Vienna, Austria

ESTRO 2023

Session

Lung
6008
Poster (Digital)
Clinical
Fractionated stereotactic radiation therapy for brain metastases: Outcomes and patterns of failure
Nuria Farre, Spain
PO-1303
Pattern of failure of LD-SCLC treated with chemoradiotherapy: dependence on disease stage.
Hjoerdis Hjalting Schmidt, Denmark
PO-1305
Response to induction chemotherapy on PET/CT predicts post-RT progression in patients with NSCLC
Marie Tvilum, Denmark
PO-1306
SBRT of hilar lymph nodes from lung cancer: outcomes, toxicity and role of CTV
Margherita Rotondi, Italy
PO-1307
Survival differences of hypofractionation vs. standard-fractionation in lung cancer: a cohort study
Macarena M. Teja Ubach, Spain
PO-1309
Predictors of outcomes in patients with NSCLC treated with chemoradiotherapy & immunotherapy.
Ashley Horne, United Kingdom
PO-1310
Epidemiological, clinical and pathological characteristics of non-small cell lung cancer in Albania
Erald Karaulli, Albania
PO-1314
Association between metabolic and pathologic response after neoadjuvant CRT for NSCLC
maria gonzalez de dueñas, Spain
PO-1315
Re-irradiation of the thorax for lung malignancy: A cohort study of cancer outcomes and toxicity
Dominic Lowe, United Kingdom
PO-1316
Pneumonitis after chemoRT and durvalumab: lung damage on CT is confined to the irradiated region
Gilles Defraene, Belgium
PO-1318
Safety and Efficacy of Moderate-intensity SBRT for Ultra-central Lung tumor
Sunmin Park, Korea Republic of
PO-1319
Chest Wall toxicity after lung SBRT treatments and influential parameters.
Sandra Fernandez Alonso, Spain
PO-1320
Early cardiac toxicity in stage III non-small cell lung cancer: preliminary dosimetric analysis
Edy Ippolito, Italy
PO-1322
Body composition as a predictor of an in-field recurrence in stage III NSCLC patients
Magdalena Drozka, Poland
PO-1324
Radiomics and Dosiomics Analysis to predict Pneumonitis after Stereotactic Radioimmunotherapy
Kim Melanie Kraus, Germany
PO-1327
Comparison of short-course with long-course palliative radiotherapy for superior vena cava syndrome
Jongmoo Park, Korea Republic of
PO-1328
Survival and prognostic factors of ultra-central tumors treated with stereotactic body radiotherapy
Viola Salvestrini, Italy
PO-1329
Local control rates after MR-guided single fraction SABR for lung tumors
Hilâl Tekatli, The Netherlands
PO-1331
Risk factors for intracranial metastasis in stage III NSCLC after chemoradiation
Stephane Thibodeau, Canada
PO-1332
Breath hold for photon or proton therapy in radical radiotherapy for lung cancer: worth the effort?
Judith van der Stoep, The Netherlands
PO-1334
Prognosticator of SBRT efficacy and toxicity in early-stage NSCLC patients
David Walz, Germany
PO-1336
Recent local control rates of stage I NSCLC treated with stereotactic body radiotherapy
Kenji Makita, Japan
PO-1337
SBRT for early-stage lung cancer: outcomes from biopsy-proven and unproven lung lesions
Celia Nicolas-Boluda, Spain
PO-1338
Comparing intra- and inter-fraction motion of tumors with fiducial markers for lung SBRT
Yuki Manabe, Japan
PO-1339
Radiation therapy in patients with non-small cell lung cancer and interstitial lung abnormalities
Makoto Ito, Japan
PO-1340
Failure patterns after stereotactic body radiotherapy for lung cancer according to the T stage
Hiroshi Doi, Japan
PO-1341